Protein A vs Protein G vs Protein L: Antibody Resin Selection

1. Start With the Binding Site

The binding site determines which formats are eligible. An intact IgG or Fc fusion may bind Protein A or G; an Fab or scFv lacking Fc cannot rely on that interaction. Protein L can capture certain Fab, scFv, and domain-antibody formats because their κ variable region remains present, but λ-chain molecules and incompatible κ families do not bind.

Accessibility is as important as sequence. Conjugation, multimerization, steric crowding, partial unfolding, and aggregation can alter apparent binding. Engineered Fc mutations designed to change effector function, half-life, or Fc-receptor interaction may also affect affinity-ligand binding directly or indirectly. Use sequence knowledge to form a hypothesis, then test the actual molecule.

2. Technical Comparison

3. Select by Antibody Format

Conventional IgG

Protein A is a logical first screen for many human and recombinant IgGs, especially where platform knowledge and scalable capture are valuable. Protein G should not be treated as merely a fallback; it can be the more suitable ligand for antibodies whose Fc subclass or species binds Protein A weakly. Compare recovery and elution severity, not only binding in a static tube.

Fc-fusion proteins

An Fc fusion may bind Protein A or G if its Fc is accessible and compatible. The fusion partner can alter steric access, hydrodynamic behavior, aggregation, and proteolysis. Product-related variants may bind differently from the desired form, which can either help or complicate capture. Measure activity of both Fc and fusion partner where relevant.

Fab, scFv, and other Fc-free fragments

Protein L is attractive when the fragment contains a compatible κ variable domain. If the construct uses λ light chain, an incompatible κ family, or no light chain, another affinity ligand or a physicochemical capture step is required. For scFv and domain formats, also evaluate whether the binding surface remains folded and accessible under feed conditions.

Bispecific and multispecific antibodies

These molecules may contain engineered Fc, asymmetric chains, fragments, or non-Ig domains. A platform ligand can select for Fc-containing species but may not distinguish correctly assembled product from Fc-containing mispaired variants. Use orthogonal analytics and consider whether capture enriches an unwanted form.

4. Interpret Species and Subclass Tables Carefully

Reference tables commonly summarize relative Protein A and Protein G binding for human, mouse, rat, rabbit, goat, sheep, and other IgGs. They are useful for narrowing candidates, but their categories hide variation among individual monoclonals, ligand constructs, immobilization chemistries, and assay conditions. Human IgG3 and mouse IgG1 are often cited as cases where Protein G may outperform Protein A, but the exact molecule still needs confirmation.

Polyclonal preparations create another complication. They contain subclasses and variable regions with different affinity, so strong-binding species can displace weaker ones during frontal loading. The recovered pool may not reproduce the input distribution when the resin is heavily loaded. If biological function depends on breadth, compare subclass composition and antigen reactivity before and after purification.

5. Binding and Elution Conditions Can Reverse a Ranking

A resin that binds strongly at one pH or salt condition may perform poorly in the actual feed. pH, conductivity, antibody concentration, competing proteins, contact time, and matrix viscosity influence observed capacity. Clarified cell-culture supernatant, serum, ascites, and a formulated antibody each present a different competition and fouling environment.

Elution is equally important. Stronger binding can increase capacity but require lower pH or longer exposure, reducing monomer recovery or activity. A slightly lower-capacity ligand that releases the antibody at a milder condition may deliver more usable product. Develop binding and elution as one cycle rather than selecting on capacity first and solving product damage later.

When testing acidic elution, record pool pH as it changes during collection. Small early fractions can be more acidic than the final mixed pool. Neutralization should be defined by addition order, mixing, base concentration, temperature, target pH, and time. If a low-pH viral inactivation hold is required, its pH and duration are separate process requirements and should not be confused with the shortest possible column elution exposure.

6. Compare the Finished Resin, Not Only the Ligand

Media sharing the same ligand can differ in matrix chemistry, rigidity, particle-size distribution, pore architecture, ligand density, coupling orientation, spacer, pressure tolerance, and alkaline stability. These attributes determine accessible dynamic capacity, pressure–flow response, wash efficiency, cleaning, and usable lifetime.

• Dynamic binding capacity: report target, feed, residence time, bed height, and breakthrough criterion.
• Matrix and pores: confirm that the antibody or fragment can access ligand-bearing surfaces without excessive diffusion limitation.
• Ligand construct: know whether native binding domains have been removed or engineered and whether that changes specificity or cleaning stability.
• Leaching: compare residual ligand in the product pool across cycles using a fit-for-purpose assay.
• Chemical compatibility: evaluate matrix, linker, and ligand under binding, elution, cleaning, sanitization, and storage conditions.

Creative BioMart offers antibody affinity chromatography media, a Protein L affinity resin, and prepacked affinity cartridges. Product specifications should be confirmed for the intended molecule and scale.

7. A Decision-Oriented Screening Plan

1. Confirm identity and format. Record species, isotype, subclass, Fc sequence, κ/λ light chain, variable-domain family where known, and all engineered changes.
2. Establish stability boundaries. Measure monomer, aggregation, recovery, and activity across candidate pH and hold conditions.
3. Run small-scale binding screens. Use representative feed and include nonbinding or blank controls when nonspecific adsorption is possible.
4. Develop wash and elution. Track target and relevant impurities in every fraction.
5. Confirm under flow. Measure DBC at relevant residence times, pressure, eluate concentration, and pool quality.
6. Challenge the cycle. Study regeneration, cleaning, storage, and repeated cycles before declaring a reusable process.

Rank candidates using weighted criteria tied to the step objective. For research purification, recovery, activity, time, and ease of use may dominate. For process development, include productivity, impurity clearance, ligand leakage, buffer use, packing, lifetime, documentation, and supply.

8. Selection Scenarios

9. Common Selection Errors

• Assuming every human IgG binds Protein A equally.
• Choosing Protein G solely from a species chart without testing the individual monoclonal.
• Calling a fragment “κ-containing” without confirming Protein L-compatible framework binding.
• Comparing supplier capacity values measured with different targets or residence times.
• Optimizing capture yield while ignoring elution-induced aggregate or loss of activity.
• Using a batch-binding result as proof of packed-bed performance.
• Deferring cleaning, leakage, and reuse studies until after resin selection.

References

1. Page M, Thorpe R. Protein A and Protein G purification of antibodies. Methods Mol Biol. 2019;1904:11–24. PMID:30602558.
2. Zarrineh M, et al. Mechanism of antibodies purification by Protein A. Anal Biochem. 2020;609:113909. doi:10.1016/j.ab.2020.113909.
3. Weinberg J, et al. Polyclonal and monoclonal IgG binding on Protein A resins. Biotechnol Bioeng. 2017;114:1803–1812. doi:10.1002/bit.26286.